SU2Cscience
@SU2Cscience
SU2C's research programs prioritize the most promising new treatments for cancer. Follow us for updates on our research + funding. Also follow @SU2C for more.
Gerrit Meijer from the @SU2C-@kwf_nl MEDOCC team presented the Team’s work in developing the multi-target FIT test for colorectal cancer at the @NKI_nl Early Cancer Detection Conference #StandUpToCancer #NetherlandsCancerInstitute #colorectalcancer
Request for Applications! The @SU2C - @CR_UK Prevention, Early Stage Detection, and Interception of Recurrence Challenge is now open! For more information, please click the link below or search Stand Up To Cancer in Proposal Central under Grant Opportunities. #EarlyDetection…
According to a paper published in @Cancer_Cell by the @SU2C Colorectal Cancer Dream, they have been able to use mutagenic agents to engineer an MMRd genotype in immunoresistant cells to generate an immunogenic phenotype cell.com/cancer-cell/ab…
The GBM chatbot is going live on the @SU2C website on 7/16. This AI companion was developed by Jason Binder after his wife was diagnosed with glioblastoma to help patients and family members to understand glioblastoma, explore options, and feel less alone on this journey. #GBMDay
A project initiated by the @SU2C Breast Cancer Dream Team was published in @Nature_NPJ Precision Oncology utilizing cohort-level and individual networks to predict best response in patients with metastatic triple negative breast cancer nature.com/articles/s4169…
New Request for Applications! The @SU2C Lung Cancer Early Detection Challenge is now open! For more information, please click the link below or search Stand Up To Cancer in Proposal Central under Grant Opportunities. #LungCancer #EarlyDetection #StandUpToCancer…
J. Silvio Gutkind @UCSanDiego, a member of the @SU2C-Fanconi Cancer Foundation- @FarrahFawcettFN Head & Neck Research Team, presented a talk entitled "Repurposing metformin for oral cancer precision prevention: Halting the malignant reprogramming of epithelial stem cells" at the…
The @SU2C Multiple Myeloma Dream Team published in @NatureGenet describing their MM precursor genomic map in order to better inform risk assessment and monitoring of MM precursor conditions. nature.com/articles/s4158…
Taha Merghoub from @WeillCornell describes the role of innate immunity in the tumor microenvironment at the @NYASciences #cancerimmunology symposium.
Wonderful talk at @NYASciences #cancerimmunotherapy conference by Anca Apavaloaei from @WeillCornell describing novel targets for #gastroesophageal cancer, including LINE-1.
Toni Ribas from @UCLAHealth kicks off the @NYASciences #cancerimmunotherapy conference at @WeillCornell describing the basic rules for PD-1 response to immunotherapy.
Check out the upcoming @NYASciences Frontiers in Cancer Immunology Symposium. The event features a number of current and former @SU2C – funded researchers, including @bengrbm, @JimAllisonPhD, Antoni Ribas, Taha Merghoub, and Padmanee Sharma. #immunology #cancer…
Research by the @VAInstitute-@SU2C Epigenetics Dream Team defines the ASCL1-FOXA2 axis as a critical driver of multiorgan SCLC metastasis according to a paper just published in @NatureComms nature.com/articles/s4146…
A new method reveals unexpected behavior in molecular crowding during cell state transitions suggesting density as a biomarker for functional precision medicine according to a paper in @natBME from @SU2C Convergence 3.1416 Research Team member Scott Manalis @MIT…
Noninvasive mutation and fragmentation-based cfDNA approaches are able to identify therapeutic response of individuals with pancreatic cancer according to a paper in @ScienceAdvances by Victor Velculescu @HopkinsMedicine of the @SU2C-@kwf_nl and @SU2C-@LungAssociation-@LUNGevity…
Noninvasive mutation and fragmentation-based cfDNA approaches are able to identify therapeutic response of individuals with pancreatic cancer according to a paper in @ScienceAdvances by Victor Velculescu @HopkinsMedicine of the @SU2C-@kwf_nl and @SU2C-@LungAssociation-@LUNGevity…
Noninvasive mutation and fragmentation-based cfDNA approaches are able to identify therapeutic response of individuals with pancreatic cancer according to a paper in @ScienceAdvances by Victor Velculescu @HopkinsMedicine of the @SU2C-@kwf_nl and @SU2C-@LungAssociation-@LUNGevity…
Work from the @SU2C Convergence 3.1416 Research Team led by Dan Littman @nyulangone and a @SU2C Sharp Award was published in @Nature describing how dendritic cells are able to regulate T cell responses to food and microbes and contribute to food tolerance nature.com/articles/s4158…
Outstanding preclinical work being done by @parasvi_patel and the team at @MGHCancerCenter and @harvardmed in support of the @SU2C Catalyst®️ @bmsnews Team! #KRAS #Mirati #colorectalcancer #aacr25
